ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Biotechnology

Healthcare
$10.90 +1.40%

+$0.44 today

Market cap
$563.78M
Beta
1.42
P/E (TTM)
-9.8
EPS (TTM)
-$3.22
52W Low $16.10High $33.62

Volume 2.70M

Average 0.50M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$160.59M

FY 2025 · Annual

Investing Cash Flow

-$71.23M

FY 2025 · Annual

Financing Cash Flow

$203.06M

FY 2025 · Annual

+8.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(51.61M)(36.91M)(69.33M)(80.49M)(166.31M)
Depreciation & Amortization0000(3.03M)
Deferred Income Tax00000
Stock-Based Compensation66.67K424K895K3.21M12.52M
Change in Working Capital(3.94M)(7.15M)12.6M7.07M(3.77M)
Accounts Receivables00000
Inventory00000
Accounts Payables293K2.8M1.38M(751K)2.14M
Other Working Capital(4.23M)(9.95M)11.22M7.82M(5.92M)
Other Non-Cash Items42.96M0000
Operating Cash Flow(12.59M)(43.63M)(55.84M)(70.21M)(160.59M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00(25M)(194.16M)(272.93M)
Sales of Investments0025M1.7M201.71M
Other Investing Activities(40M)0000
Investing Cash Flow(40M)00(192.47M)(71.23M)
Debt Repayment00000
Common Stock Issued89.87M2K354K185.95M202.63M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities015K(2.06M)631K(70K)
Financing Cash Flow89.87M169.72M42.86M186.58M203.06M
Effect of Forex Changes00000
Net Change in Cash37.28M126.09M(12.98M)(76.1M)(28.75M)
Free Cash Flow(12.59M)(43.63M)(55.84M)(70.21M)(160.59M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$166.3M
+ D&A-$3.0M
+ Stock-Based Comp$12.5M
+ Deferred Tax$0
- Working Capital-$3.8M
+ Other Non-Cash$0
= Operating Cash Flow-$160.6M
- Capex$0
= Free Cash Flow-$160.6M

Analysis

FY2025 free cash flow is -$160.6M. FCF conversion is 96.6% of net income. Operating cash flow was -$160.6M, with capex of $0. The largest bridge item is Stock-Based Comp at $12.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
10-QQuarterly reportNov 9, 2026
SC 13G/ASC 13G/A filingNov 5, 2026
4Statement of changes in beneficial ownershipNov 2, 2026
8-KCurrent reportOct 26, 2026

Does AVBP generate free cash flow?

ArriVent BioPharma, Inc. Common Stock (AVBP) generated -$160.59M of free cash flow in fiscal 2025.

How much operating cash flow does AVBP produce?

Operating cash flow was -$160.59M, before capital expenditures of $0.00.